Moreover, to target cancer cells, NPs and μPs surfaces can be modified to increase the interaction with plasma membrane-specific markers like the transferrin receptor [18], the folate receptor [19], or the human epidermal growth factor receptor 2 (HER2, also known as ERBB2) [20,21]. The gene discussed is ERBB2; the disease is cancer.